全球畅销药TOP100: Revision history

From Linix VServer
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

19 November 2025

  • curprev 09:4109:41, 19 November 2025KarolynMcGruder talk contribs 5,037 bytes +5,037 Created page with "<br><br><br>默沙东的15价肺炎球菌结合疫苗Vaxneuvance在2024年销售额稳定在6.65亿美元,对Prevnar系列构成一定竞争。 此外,Vaxcyte正在开发的24价肺炎球菌疫苗VAX-31在临床试验中显示出更广泛的血清型覆盖和相当的安全性,可能成为Prevnar系列的潜在威胁。 尽管Biktarvy在HIV治疗领域占据重要地位,但市场竞争依然激烈。 其他HIV治疗药物如GSK的Dovato和ViiV的Cabenuva等也在..."